| scholarly article | Q13442814 |
| P50 | author | Bruno Coudert | Q51368266 |
| P2093 | author name string | Guy Jerusalem | |
| Mario Campone | |||
| Thierry Petit | |||
| Jean-Pascal Machiels | |||
| Christelle Lévy | |||
| Gilles Romieu | |||
| Marc Beauduin | |||
| Bernard Asselain | |||
| Henri Roché | |||
| Marc Spielmann | |||
| Hubert Orfeuvre | |||
| Bruno Coudert | |||
| Corinne Veyret | |||
| Anne-Laure Martin | |||
| Jean-Luc Canon | |||
| Bruno Audhuy | |||
| Jean-Christophe Eymard | |||
| Daniel Serin | |||
| Gilles Piot | |||
| Frédérique Pénault-Llorca | |||
| UNICANCER Breast Group | |||
| P2860 | cites work | Taxanes for adjuvant treatment of early breast cancer | Q24242987 |
| Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial | Q24597456 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. | Q32107791 | ||
| Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial | Q33397151 | ||
| Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer | Q33561953 | ||
| Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer | Q33996115 | ||
| Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer | Q34109991 | ||
| Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer | Q34601123 | ||
| Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials | Q35740423 | ||
| Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients | Q36609527 | ||
| Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197 | Q37125089 | ||
| Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. | Q37155629 | ||
| Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial | Q37206289 | ||
| Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer | Q37649479 | ||
| Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials | Q42512902 | ||
| Adjuvant docetaxel for high-risk, node-negative breast cancer | Q42788947 | ||
| BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. | Q43006197 | ||
| Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. | Q44362100 | ||
| Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. | Q44648834 | ||
| Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer | Q44902909 | ||
| Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy | Q44935773 | ||
| Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer | Q46043815 | ||
| Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. | Q46127853 | ||
| Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. | Q46570397 | ||
| Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. | Q46573303 | ||
| Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group | Q46691182 | ||
| Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. | Q46817262 | ||
| Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials | Q46828225 | ||
| HER2 and Response to Paclitaxel in Node-Positive Breast Cancer | Q57578418 | ||
| Benefit of taxanes as adjuvant chemotherapy for early breast cancer | Q61899631 | ||
| Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial | Q66829419 | ||
| c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer | Q72673347 | ||
| Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials | Q83309689 | ||
| Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer | Q84244064 | ||
| P433 | issue | 7 | |
| P921 | main subject | fluorouracil | Q238512 |
| docetaxel | Q420436 | ||
| P304 | page(s) | 900-909 | |
| P577 | publication date | 2012-05-18 | |
| P1433 | published in | Oncologist | Q2122327 |
| P1476 | title | Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial | |
| P478 | volume | 17 |
| Q59050832 | A Phase IV Clinical Trial of Patients with Solid Tumors Receiving Lenograstim as Primary Prophylaxis for Chemotherapy-Induced Neutropenia, in a Docetaxel-Based Regimen |
| Q26853619 | Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline |
| Q41706289 | Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario |
| Q34379034 | Benefit risk assessment and update on the use of docetaxel in the management of breast cancer |
| Q35786472 | Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis |
| Q59340503 | Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis |
| Q35239634 | Optimal systemic therapy for early breast cancer in women: a clinical practice guideline |
| Q33698286 | Presentation and management of docetaxel-related adverse effects in patients with breast cancer |
| Q26798078 | Progress in adjuvant chemotherapy for breast cancer: an overview |
| Q37174738 | Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study |
| Q47107032 | Randomized controlled trial of late-course concurrent versus sequential chemoradiotherapy after mastectomy and axillary surgery in locally advanced breast cancer |
| Q55096327 | The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 tria |
Search more.